

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

February 15, 2024

Date of Report (Date of Earliest Event Reported)

ULTRALIFE CORPORATION

(Exact name of registrant as specified in its charter)

Delaware

(State of incorporation)

000-20852

(Commission File Number)

16-1387013

(IRS Employer Identification No.)

2000 Technology Parkway, Newark, New York 14513

(Address of principal executive offices) (Zip Code)

(315) 332-7100

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

**Common Stock, \$0.10 par value per
share**

(Title of each class)

ULBI

(Trading Symbol)

NASDAQ

(Name of each exchange on which registered)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging Growth Company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02 Results of Operations and Financial Condition

On February 15, 2024, Ultralife Corporation issued a press release regarding the financial results for its fourth quarter and full year ended December 31, 2023. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by this reference.

Item 9.01 Financial Statements, Pro Forma Financials and Exhibits

(d) Exhibits.

Exhibit Number	Exhibit Description
99.1	Press Release of Ultralife Corporation dated February 15, 2024
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 15, 2024

ULTRALIFE CORPORATION

By: /s/ Philip A. Fain
Philip A. Fain
Chief Financial Officer and Treasurer



Ultralife Corporation Reports Fourth Quarter Results

NEWARK, N.Y. – February 15, 2024 -- Ultralife Corporation (NASDAQ: ULBI) reported operating results for the fourth quarter and full year ended December 31, 2023.

Fourth Quarter Highlights:

- Sales of \$44.5 million representing a 23.4% year-over-year increase
- Highest medical sales quarter in Company's history
- Operating income of \$3.6 million versus \$0.2 million for the 2022 fourth quarter
- Adjusted EPS of \$0.18 compared to a loss of \$0.03 for the 2022 fourth quarter
- Adjusted EBITDA of \$4.8 million representing a 134.8% year-over-year increase
- Backlog of \$103.5 million exiting 2023, a 2.4% sequential increase over third quarter

Fiscal Year 2023 Highlights:

- Sales of \$158.6 million representing a 20.3% year-over-year increase
- Operating income of \$9.5 million versus \$0.1 million for 2022
- Adjusted EPS of \$0.52 compared to a loss of \$0.07 for 2022
- Adjusted EBITDA of \$15.7 million representing a 138.8% year-over-year increase

“Ultralife performed exceedingly well in the fourth quarter, delivering higher Communications Systems revenue, a 360-basis point expansion of Battery & Energy Products’ gross margin and operating expense leverage. In addition, medical sales reached the highest quarterly level since we entered this market in 2012. With adjusted EBITDA more than doubling and inventory levels lower, we are well positioned to commence paying down our acquisition debt,” said Mike Manna, President and Chief Executive Officer.

“Our strong fourth quarter performance caps a year of accomplishment against our stated highest priority of recapturing gross margin through price realization activities, supply chain improvements, level-loaded production and lean manufacturing initiatives. These actions resulted in a 240-basis point expansion of gross margin for the year to 24.7% and a swing from a loss to adjusted EPS of \$0.52. Finally, our efforts to strengthen our commercial relationships launching customer-driven new products into the market have been bearing fruit and sustained our backlog in excess of \$100 million,” added Mr. Manna.

“As we enter 2024 with a healthy backlog and a significantly stronger balance sheet, we are focused on driving additional gross margin expansion, organic growth in our end markets and operating leverage. We will continue to invest in new product development for commercial expansion. Our focus in 2024 is to build upon our 2023 momentum, sustain profitable growth and generate incremental cash flow to reduce debt, and support strategic capital expenditures and accretive acquisitions,” concluded Mr. Manna.

Fourth Quarter 2023 Financial Results

Revenue was \$44.5 million, an increase of \$8.4 million, or 23.4%, as compared to revenue of \$36.1 million for the fourth quarter of 2022. Overall, government/defense sales increased 28.8% and commercial sales increased 20.2% over the 2022 period. Battery & Energy Products sales increased 11.1% to \$35.7 million compared to \$32.1 million last year reflecting increases of 20.2% in commercial sales, including a 118.0% increase in medical battery sales, partially offset by decreases of 11.3% in oil & gas market sales and 11.4% in government/defense sales. Communications Systems sales increased by 121.9% to \$8.8 million compared to \$4.0 million for the same period last year, primarily attributable to shipments of vehicle-amplifier adaptors to a global defense contractor for the U.S. Army and of integrated systems of amplifiers and radio vehicle mounts to a major international defense contractor under an ongoing allied country government/defense modernization program. Our total backlog exiting the 2023 fourth quarter was \$103.5 million representing a 2.4% sequential increase over that reported for the third quarter.

Gross profit was \$11.4 million, or 25.6% of revenue, compared to \$8.1 million, or 22.4% of revenue, for the same quarter a year ago. Battery & Energy Products gross margin was 25.2%, compared to 21.6% last year, primarily due to more efficiencies and higher cost absorption resulting from a concerted effort to level-load production more evenly across the 2023 quarter, as well as improved price realization. Communications Systems gross margin was 27.2% compared to 28.7% last year, primarily due to inefficiencies caused by component delays from suppliers, partially offset by higher factory volume.

Operating expenses were \$7.8 million, compared to \$7.9 million for the 2022 fourth quarter. Operating expenses were 17.4% of revenue compared to 21.8% of revenue for the year-earlier period.

The combination of higher sales leveraged by improved gross margin and operating expenses resulted in a \$3.4 million increase in operating income to \$3.6 million from \$0.2 million last year.

Net income was \$2.9 million or \$0.17 per diluted share on a GAAP basis, compared to a net loss of \$0.2 million or \$0.01 per diluted share for the fourth quarter of 2022. Adjusted EPS was \$0.18 on a diluted basis for the fourth quarter of 2023, compared to a loss of \$0.03 for the 2022 period. Adjusted EPS excludes the provision for deferred taxes which primarily represents non-cash charges for U.S. taxes which we expect will be fully offset by net operating loss carryforwards and other tax credits for the foreseeable future.

Adjusted EBITDA, defined as EBITDA including non-cash, stock-based compensation expense, was \$4.8 million for the fourth quarter of 2023, or 10.7% of sales, compared to \$2.0 million, or 5.6% of sales, for the year-earlier period.

See the “Non-GAAP Financial Measures” section of this release for a reconciliation of adjusted EPS to EPS and adjusted EBITDA to net income attributable to Ultralife Corporation.

About Ultralife Corporation

Ultralife Corporation serves its markets with products and services ranging from power solutions to communications and electronics systems. Through its engineering and collaborative approach to problem solving, Ultralife serves government/defense and commercial customers across the globe.

Headquartered in Newark, New York, the Company's business segments include Battery & Energy Products and Communications Systems. Ultralife has operations in North America, Europe and Asia. For more information, visit www.ultralifecorporation.com.

Conference Call Information

Ultralife will hold its fourth quarter earnings conference call today at 8:30 AM ET.

To ensure a fast and reliable connection to our investor conference call, we now require participants dialing in by phone to register using the following link prior to the call: <https://register.vevent.com/register/BI9f2b6fae66954f53b4517cbe89148738>. This will eliminate the need to speak with an operator. Once registered, dial-in information will be provided along with a personal identification number. Should you register early and misplace your details, you can simply click back on this same link at any time to register and view this information again. A live webcast of the conference call will be available to investors in the Events & Presentations section of the Company's website at <http://investor.ultralifecorporation.com>. For those who cannot listen to the live broadcast, a replay of the webcast will be available shortly after the call at the same location.

This press release may contain forward-looking statements based on current expectations that involve a number of risks and uncertainties. The potential risks and uncertainties that could cause actual results to differ materially include the impact of COVID-19 and related supply chain disruptions, potential reductions in revenues from key customers, acceptance of our new products on a global basis and uncertain global economic conditions. The Company cautions investors not to place undue reliance on forward-looking statements, which reflect the Company's analysis only as of today's date. The Company undertakes no obligation to publicly update forward-looking statements to reflect subsequent events or circumstances. Further information on these factors and other factors that could affect Ultralife's financial results is included in Ultralife's Securities and Exchange Commission (SEC) filings, including the latest Annual Report on Form 10-K.

ULTRALIFE CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(Dollars in Thousands)
(Unaudited)

ASSETS

	December 31, 2023	December 31, 2022
Current Assets:		
Cash	\$ 10,278	\$ 5,713
Trade Accounts Receivable, Net	31,761	27,779
Inventories, Net	42,215	41,192
Prepaid Expenses and Other Current Assets	5,949	4,304
Total Current Assets	<u>90,203</u>	<u>78,988</u>
Property, Plant and Equipment, Net	21,117	21,716
Goodwill	37,571	37,428
Other Intangible Assets, Net	15,107	15,921
Deferred Income Taxes, Net	10,567	12,069
Other Non-Current Assets	3,711	2,308
Total Assets	<u>\$ 178,276</u>	<u>\$ 168,430</u>

LIABILITIES AND SHAREHOLDERS' EQUITY

Current Liabilities:		
Accounts Payable	\$ 11,336	\$ 16,074
Current Portion of Long-Term Debt	2,000	2,000
Accrued Compensation and Related Benefits	3,115	2,890
Accrued Expenses and Other Current Liabilities	7,279	7,949
Total Current Liabilities	<u>23,730</u>	<u>28,913</u>
Long-Term Debt, Net	23,624	19,310
Deferred Income Taxes	1,714	1,917
Other Non-Current Liabilities	3,781	1,887
Total Liabilities	<u>52,849</u>	<u>52,027</u>
Shareholders' Equity:		
Common Stock	2,078	2,057
Capital in Excess of Par Value	189,160	187,405
Accumulated Deficit	(40,754)	(47,951)
Accumulated Other Comprehensive Loss	(3,660)	(3,750)
Treasury Stock	(21,492)	(21,484)
Total Ultralife Equity	<u>125,332</u>	<u>116,277</u>
Non-Controlling Interest	95	126
Total Shareholders' Equity	<u>125,427</u>	<u>116,403</u>
Total Liabilities and Shareholders' Equity	<u>\$ 178,276</u>	<u>\$ 168,430</u>

ULTRALIFE CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
(In Thousands Except Per Share Amounts)
(Unaudited)

	Three-Month Period Ended		Year Ended	
	December 31, 2023	December 31, 2022	December 31, 2023	December 31, 2022
Revenues:				
Battery & Energy Products	\$ 35,703	\$ 32,122	\$ 129,953	\$ 119,995
Communications Systems	8,845	3,985	28,691	11,845
Total Revenues	<u>44,548</u>	<u>36,107</u>	<u>158,644</u>	<u>131,840</u>
Cost of Products Sold:				
Battery & Energy Products	26,711	25,185	99,178	93,841
Communications Systems	6,435	2,841	20,266	8,599
Total Cost of Products Sold	<u>33,146</u>	<u>28,026</u>	<u>119,444</u>	<u>102,440</u>
Gross Profit	<u>11,402</u>	<u>8,081</u>	<u>39,200</u>	<u>29,400</u>
Operating Expenses:				
Research and Development	1,852	1,656	7,531	7,081
Selling, General and Administrative	5,901	6,208	22,194	22,190
Total Operating Expenses	<u>7,753</u>	<u>7,864</u>	<u>29,725</u>	<u>29,271</u>
Operating Income	<u>3,649</u>	<u>217</u>	<u>9,475</u>	<u>129</u>
Other Expense	<u>536</u>	<u>597</u>	<u>358</u>	<u>575</u>
Income (Loss) Before Income Taxes	<u>3,113</u>	<u>(380)</u>	<u>9,117</u>	<u>(446)</u>
Income Tax Provision (Benefit)	<u>263</u>	<u>(155)</u>	<u>1,951</u>	<u>(326)</u>
Net Income (Loss)	<u>2,850</u>	<u>(225)</u>	<u>7,166</u>	<u>(120)</u>
Net Loss Attributable to Non-Controlling Interest	<u>(23)</u>	<u>(1)</u>	<u>(31)</u>	<u>(1)</u>
Net Income (Loss) Attributable to Ultralife Corporation	<u>\$ 2,873</u>	<u>\$ (224)</u>	<u>\$ 7,197</u>	<u>\$ (119)</u>
Net Income (Loss) Per Share Attributable to Ultralife Common Shareholders – Basic				
	<u>\$.18</u>	<u>\$ (.01)</u>	<u>\$.44</u>	<u>\$ (.01)</u>
Net Income (Loss) Per Share Attributable to Ultralife Common Shareholders – Diluted				
	<u>\$.17</u>	<u>\$ (.01)</u>	<u>\$.44</u>	<u>\$ (.01)</u>
Weighted Average Shares Outstanding – Basic	<u>16,338</u>	<u>16,135</u>	<u>16,214</u>	<u>16,125</u>
Weighted Average Shares Outstanding – Diluted	<u>16,479</u>	<u>16,135</u>	<u>16,226</u>	<u>16,125</u>

Non-GAAP Financial Measures

Adjusted EBITDA

In evaluating our business, we consider and use adjusted EBITDA, a non-GAAP financial measure, as a supplemental measure of our operating performance in addition to U.S. Generally Accepted Accounting Principles (“GAAP”) financial measures. We define adjusted EBITDA as net income attributable to Ultralife Corporation before net interest expense, provision (benefit) for income taxes, depreciation and amortization, and stock-based compensation expense, plus/minus expense/income that we do not consider reflective of our ongoing continuing operations. We reconcile adjusted EBITDA to net income attributable to Ultralife Corporation, the most comparable financial measure under GAAP. Neither current nor potential investors in our securities should rely on adjusted EBITDA as a substitute for any GAAP measures and we encourage investors to review the following reconciliation of adjusted EBITDA to net income attributable to Ultralife Corporation.

ULTRALIFE CORPORATION AND SUBSIDIARIES
CALCULATION OF ADJUSTED EBITDA
(Dollars in Thousands)
(Unaudited)

	<u>Three-Month Period Ended</u>		<u>Year Ended</u>	
	<u>December</u> <u>31, 2023</u>	<u>December</u> <u>31, 2022</u>	<u>December</u> <u>31, 2023</u>	<u>December</u> <u>31, 2022</u>
Net Income (Loss) Attributable to Ultralife Corporation	\$ 2,873	\$ (224)	\$ 7,197	\$ (119)
Adjustments:				
Interest Expense, Net	566	368	2,016	951
Income Tax Provision (Benefit)	263	(155)	1,951	(326)
Depreciation Expense	740	727	3,022	3,177
Amortization Expense	226	313	889	1,282
Stock-Based Compensation Expense	104	224	528	776
Cyber-Insurance Policy Deductible	-	-	100	-
Non-Cash Purchase Accounting Adjustment	-	-	-	55
Severance to Former President & CEO	-	779	-	779
Adjusted EBITDA	<u>\$ 4,772</u>	<u>\$ 2,032</u>	<u>\$ 15,703</u>	<u>\$ 6,575</u>

Adjusted Earnings Per Share

In evaluating our business, we consider and use adjusted EPS, a non-GAAP financial measure, as a supplemental measure of our business performance. We define adjusted EPS as net income attributable to Ultralife Corporation excluding the provision (benefit) for deferred income taxes divided by our weighted average shares outstanding on both a basic and diluted basis. We believe that this information is useful in providing period-to-period comparisons of our results by reflecting the portion of our tax provision that we expect will be predominantly offset by our U.S. net operating loss carryforwards and other tax credits for the foreseeable future. We reconcile adjusted EPS to EPS, the most comparable financial measure under GAAP. Neither current nor potential investors in our securities should rely on adjusted EPS as a substitute for any GAAP measures and we encourage investors to review the following reconciliation of adjusted EPS to EPS and net income attributable to Ultralife Corporation.

ULTRALIFE CORPORATION AND SUBSIDIARIES CALCULATION OF ADJUSTED EPS (In Thousands Except Per Share Amounts) (Unaudited)

	Three-Month Period Ended					
	December 31, 2023			December 31, 2022		
	Amount	Per Basic Share	Per Diluted Share	Amount	Per Basic Share	Per Diluted Share
Net Income (Loss) Attributable to Ultralife Corporation	\$ 2,873	\$.18	\$.17	\$ (224)	\$ (.01)	\$ (.01)
Deferred Tax Provision (Benefit)	56	-	.01	(279)	(.02)	(.02)
Adjusted Net Income (Loss)	<u>\$ 2,929</u>	<u>\$.18</u>	<u>\$.18</u>	<u>\$ (503)</u>	<u>\$ (.03)</u>	<u>\$ (.03)</u>
Weighted Average Shares Outstanding		16,338	16,479		16,135	16,135

	Year Ended					
	December 31, 2023			December 31, 2022		
	Amount	Per Basic Share	Per Diluted Share	Amount	Per Basic Share	Per Diluted Share
Net Income (Loss) Attributable to Ultralife Corporation	\$ 7,197	\$.44	\$.44	\$ (119)	\$ (.01)	\$ (.01)
Deferred Tax Provision (Benefit)	1,301	.08	.08	(962)	(.06)	(.06)
Adjusted Net Income (Loss)	<u>\$ 8,498</u>	<u>\$.52</u>	<u>\$.52</u>	<u>\$ (1,081)</u>	<u>\$ (.07)</u>	<u>\$ (.07)</u>
Weighted Average Shares Outstanding		16,214	16,226		16,125	16,125

Company Contact:

Ultralife Corporation

Philip A. Fain

(315) 210-6110

pfain@ulbi.com

Investor Relations Contact:

LHA

Jody Burfening

(212) 838-3777

jburfening@lhai.com